Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wilding, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK

John Wilding

Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL, UK, j.p.h.wilding{at}liv.ac.uk

Guidelines for the management of type 2 diabetes mellitus from the UK National Institute for Health and Clinical Excellence and the joint American Diabetes Association/European Association for the Study of Diabetes identify a role for glucagon-like peptide 1 (GLP-1) agonists as second- or third-line treatments. In the LEAD-2 trial the GLP-1 agonist liraglutide was similar to glimepiride for glycaemic control in patients receiving background metformin. Liraglutide was generally well tolerated, with a low incidence of hypoglycaemia, and it significantly reduced body weight and systolic blood pressure compared with glimepiride. These results suggest that addition of liraglutide may help to improve glycaemic control and reduce body weight and systolic blood pressure in patients with type 2 diabetes who have unsatisfactory control with metformin. Patients who are particularly obese or for whom hypoglycaemia is problematic may be especially suitable for this agent. The future place of liraglutide in guidelines will depend on further data regarding efficacy, tolerability and long-term benefits.

Key Words: clinical trials • glucagon-like peptide • guidelines • liraglutide • type 2 diabetes.

The British Journal of Diabetes & Vascular Disease, Vol. 9, No. 4, 177-185 (2009)
DOI: 10.1177/1474651409342637
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?